Hyperfine (HYPR) Stock Price, News & Analysis

Company Overview

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

Key Stats

• Today's Range: $1.06 to $1.16
• 50-Day Range: $0.54 to $1.15
• 52-Week Range: $0.53 to $1.90
• Volume: 236,537 shs
• Average Volume: 447,712 shs
• Market Capitalization: $84.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.06
• Consensus Rating: Moderate Buy

Hyperfine Stock Analysis - MarketRank™

Hyperfine scored higher than 29% of companies evaluated by MarketBeat, and ranked 809th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hyperfine has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Hyperfine has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hyperfine are expected to grow in the coming year, from ($0.57) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hyperfine is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hyperfine is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hyperfine has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.17% of the float of Hyperfine has been sold short.

Short Interest Ratio / Days to Cover

Hyperfine has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hyperfine has recently decreased by 7.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hyperfine does not currently pay a dividend.

Dividend Growth

Hyperfine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.17% of the float of Hyperfine has been sold short.

Short Interest Ratio / Days to Cover

Hyperfine has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hyperfine has recently decreased by 7.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.97

News Sentiment

Hyperfine has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Hyperfine this week, compared to 1 article on an average week.

Search Interest

10 people have searched for HYPR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hyperfine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,610.00 in company stock.

Percentage Held by Insiders

30.98% of the stock of Hyperfine is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.03% of the stock of Hyperfine is held by institutions.

HYPR Stock Analysis - Frequently Asked Questions

How have HYPR shares performed this year?

Hyperfine's stock was trading at $0.88 at the beginning of 2025. Since then, HYPR stock has increased by 22.7% and is now trading at $1.08.

How were Hyperfine's earnings last quarter?

Hyperfine, Inc. (NASDAQ:HYPR) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $2.14 million for the quarter, compared to analysts' expectations of $2.82 million. Hyperfine had a negative trailing twelve-month return on equity of 74.19% and a negative net margin of 343.42%.
Read the conference call transcript.

How do I buy shares of Hyperfine?

Shares of HYPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hyperfine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hyperfine investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Paycom Software (PAYC), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/27/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HYPR
• CIK: 1833769
• Web: hyperfine.io
• Phone: 866-796-6767
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hyperfine: $1.06
• High Price Target: $1.50
• Low Price Target: $0.68
• Potential Upside/Downside: -1.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.72 million
• Net Margins: -343.42%
• Pretax Margin: -343.42%
• Return on Equity: -74.19%
• Return on Assets: -62.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.07
• Quick Ratio: 5.48

Sales & Book Value

• Annual Sales: $12.89 million
• Price / Sales: 6.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 1.61

Miscellaneous

• Outstanding Shares: 77,830,000
• Free Float: 53,720,000
• Market Cap: $84.06 million
• Optionable: Optionable
• Beta: 1.01